EEE5E45B-D2E3-4CFA-AC5F-8AE1EC2CB61C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 59.32982917214191
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.587
- MYC_TARGETS_V1+0.538
- DNA_REPAIR+0.527
- OXIDATIVE_PHOSPHORYLATION+0.490
- E2F_TARGETS+0.341
- WNT_BETA_CATENIN_SIGNALING+0.339
- UNFOLDED_PROTEIN_RESPONSE+0.315
- CHOLESTEROL_HOMEOSTASIS+0.312
- PANCREAS_BETA_CELLS+0.312
- G2M_CHECKPOINT+0.208
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.408
- INFLAMMATORY_RESPONSE-0.405
- UV_RESPONSE_DN-0.400
- IL6_JAK_STAT3_SIGNALING-0.372
- TNFA_SIGNALING_VIA_NFKB-0.336
- COMPLEMENT-0.334
- COAGULATION-0.295
- KRAS_SIGNALING_DN-0.294
- IL2_STAT5_SIGNALING-0.276
- HYPOXIA-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E753A375-575A-4A0D-B231-0EC8D76BAF13 | — | — | 0.923 |
| 2 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.918 |
| 3 | 85D3FB91-4738-4B8A-B86E-115FDEF10166 | — | — | 0.914 |
| 4 | DEACC29A-6DEF-4728-AFEB-15D7BDA850CA | — | — | 0.912 |
| 5 | 4EBF33F3-DA34-4866-81E5-F2D50A18D413 | — | — | 0.887 |
| 6 | 3E5F6B52-112E-4F87-B49C-061B9DFD1E2D | — | — | 0.886 |
| 7 | 208643FA-0388-44A3-8131-B41AC280107C | — | — | 0.881 |
| 8 | C3818F8D-4E33-40AA-8863-E1CD71505597 | — | — | 0.870 |
| 9 | ERR2598212 | fetal | fetal | 0.866 |
| 10 | 5F991EDF-3871-4111-9A04-BF6CA02648CA | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.587 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.538 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.527 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.341 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.339 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.315 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.312 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.312 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.208 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.184 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.164 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.113 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.082 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.079 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.072 | Inavolisib | — uncovered |
| PEROXISOME | 0.024 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.023 | Idelalisib | — uncovered |